Product Images Abacavir

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 3 images provide visual information about the product associated with Abacavir NDC 69097-514 by Cipla Usa Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

111c0e04 abba 40e6 ab23 2df93e429250 01

111c0e04 abba 40e6 ab23 2df93e429250 01

111c0e04 abba 40e6 ab23 2df93e429250 02

111c0e04 abba 40e6 ab23 2df93e429250 02

Abacavir Tablets, USP is a prescription medication with NDC 69097-514-03, containing 60 tablets, each tablet containing Abacavir Sulfate USP equivalent to Abacavir 300 mg. It is manufactured by Cipla Ltd. in India, and distributed by Cipla USA, Inc. in Sunrise, FL. The medication guide and warning card from the carton should be given to the patient each time Abacavi Tablets is dispensed. The package insert should be referred to for dosage and administration guidelines. The tablets should be stored at 20°C to 25°C, and not used if the safety seal under the cap is broken or missing.*

111c0e04 abba 40e6 ab23 2df93e429250 03

111c0e04 abba 40e6 ab23 2df93e429250 03

This appears to be an output of the packaging and related details of a batch of Abacavir Tablets, USP. It includes information such as the GTIN, serial number, expiry date, lot number, dosage instructions, and storage conditions. Additionally, there are warnings and precautions such as the need to keep the medication out of reach of children, and to only use it according to the directions provided. The manufacturer's name and address are also included.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.